Company intelligence / Profile preview

Omega Financial

Boston, Massachusetts, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Omega Funds is a leading international healthcare VC focused on creating and investing in innovative life sciences companies, with a strong track record of funding and helping bring to market 52 commercialized products via its portfolio; it has backed numerous successful exits via IPO and acquisition, and is active in both the US and Europe

Therapeutic areas: OncologyOtherImmunologyRare Diseases
Industry: Investors

Partnerships

Numerous, as an investor in many biotechs; notable exits include Scorpion Therapeutics (acquired by Eli Lilly)EyeBio (acquired by Merck)Bicara TherapeuticsMorphic Therapeutic

Beyond the preview

Go deeper on Omega Financial.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omega Financial.

Explore the full profile